The impact of tumor invasion to muscularis mucosaevascular plexus on patient outcome in pT1 bladder urothelial carcinoma
Objectives: T1 bladder cancer has a wide range of tumor behavior and lamina propria invasion depth has a high potential risk of disease progression. To evaluate the patient outcome according to the tumor invasion to the muscularis mucosae-vascular plexus (MM-VP) in pT1 bladder urothelial carcinoma (BUC).
Materials and methods: This study is a retrospective analysis of patients consecutively recorded from 2007 to 2013. A total of 93 patients with a history of primary pT1 BUC and complete follow-up were included. We used a pathological substaging system according to the tumor invasion regarding the MM-VP: pT1a (invasion above MM-VP) and pT1b (MM-VP invasion). We evaluated recurrence-free survival (RFS), progression- free survival (PFS), disease-specific-survival (DSS) based on this sub-staging system.
Results: Pathological evaluation regarding the MM-VP invasion revealed 53 patients (57%) as pT1a BUC and 40 patients (43%) as pT1b BUC. The mean follow-up was 78.8 months. During the follow-up period; 60 patients (64.5%) had tumor recurrences, 32 patients (34.4%) had progression to invasive disease, 18 patients (19.4 %) died during follow-up related to the BUC. In 29 (54.7%) of pT1a and in 31(77.5%) of pT1b tumors, the recurrent disease was recorded during the followup period (p = 0.023). DSS rates at 5 years for pT1a and pT1b were 80.2% and 60.8%, respectively. PFS, RFS, and DSS rates were similar for pT1a/pT1b and did not reach statistical significance (p > 0.05).
Conclusions: Sub-staging of pT1 BUC according to the MM-VP invasion showed a limited impact on the outcome in our patient cohort. However, the presence of pT1b disease caused a significantly higher rate of recurrence.
van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009 Sep;56(3):430-42. PubMed PMID: 19576682.
Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan;63(1):36-44. PubMed PMID: 22981672.
Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007 Dec;178(6):2314-30. PubMed PMID: 17993339.
Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010 Jan;57(1):60-70. PubMed PMID: 19740595.
Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol. 2016 Jan;69(1):60-9. PubMed PMID: 26210894.
Ozkaptan O, ;Çubuk, Alkan; Dinçer, Erdinç; Şahan, Ahmet; Kafkaslí, Alper; Akça, Oktay. Extraperitoneal Antegrade vs Transperitoneal Open Radical Cystectomy: Single Center Experiences with 200 Cases Bladder cancer. 2020.
Budak S, Yucel C, Keskin MZ, et al. Pathology outcomes in patients with transurethral bladder tumour resection in a Turkish population: A retrospective analysis. Arch Ital Urol Androl. 2018 Mar 31;90(1):8-10. PubMed PMID: 29633791. Epub 2018/04/11.
Mathieu R, Lucca I, Roupret M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016 Aug;13(8):471-9. PubMed PMID: 27431340.
Breyer J.1 BS, Müller A.2, Lausenmeyer E-M.1, Mayr R.1, Gierth M.1, Burger M.1, Denzinger S.1, Hartmann A.2, Otto W.1. New pathological features predicting prognosis of early-invasive urothelial carcinoma: Quantitative substaging and tumour invasion pattern should assist WHO 1973 grading classification in predicting cancer-specific survival of stage pT1 bladder cance. Eur Urol Suppl 2016;15(3):e392.
Naselli A, Hurle R, Paparella S, et al. Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2017 Jan 13. PubMed PMID: 28753839.
Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 1990 Aug 1;66(3):543-8. PubMed PMID: 2364365.
van Rhijn BW, van der Kwast TH, Alkhateeb SS, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol. 2012 Feb;61(2):378-84. PubMed PMID: 22036775.
Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005 Aug;48(2):231-8; discussion 8. PubMed PMID: 15963635.
Turan T, Efiloglu O, Gunaydin B, et al. Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder. Int Braz J Urol. 2018 Mar-Apr;44(2):267-72. PubMed PMID: 29219283. Pubmed Central PMCID: PMC6050560.
Babjuk M, Bohle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017 Mar;71(3):447-61. PubMed PMID: 27324428.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106-19. PubMed PMID: 26996659.
Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes JA. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology. 1998 Dec;52(6):1009-13; discussion 13-4. PubMed PMID: 9836546.
Lee JY, Joo HJ, Cho DS, Kim SI, Ahn HS, Kim SJ. Prognostic Significance of Substaging according to the Depth of Lamina Propria Invasion in Primary T1 Transitional Cell Carcinoma of the Bladder. Korean J Urol. 2012 May;53(5):317-23. PubMed PMID: 22670190. Pubmed Central PMCID: PMC3364470.
Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF. Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol. 1996 Nov;9(11):1035-9. PubMed PMID: 8933512.
V DEM, Cerruto MA, D'Elia C, et al. Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. Mol Clin Oncol. 2014 Jul;2(4):575-80. PubMed PMID: 24940498. Pubmed Central PMCID: PMC4051551.
Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol. 1997 Mar;157(3):800-3; discussion 4. PubMed PMID: 9072570.
Amin MB, McKenney JK, Paner GP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur Urol. 2013 Jan;63(1):16-35. PubMed PMID: 23083804.
Ro JY, Ayala AG, el-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol. 1987 Sep;11(9):668-73. PubMed PMID: 3631381.
Roupret M, Seisen T, Comperat E, et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol. 2013 Jun;189(6):2069-76. PubMed PMID: 23201497.
Soukup V, Duskova J, Pesl M, et al. The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. Urol Int. 2014;92(2):150-6. PubMed PMID: 24481124.
Patriarca C, Hurle R, Moschini M, et al. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagn Pathol. 2016 Jan 20;11:6. PubMed PMID: 26791567. Pubmed Central PMCID: PMC4721190.
Gershman B, Boorjian SA, Hautmann RE. Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? Bladder Cancer. 2015 Sep 5;2(1):1-14. PubMed PMID: 27376120. Pubmed Central PMCID: PMC4927848. Epub 2015/01/01.
- Abstract views: 223
- PDF: 126
Copyright (c) 2020 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.